

Mini Review

Domination of Gastric Complications among Diabetic Patients

Abdul Kader Mohiuddin*

Assistant Professor, Department of Pharmacy, World University of Bangladesh

***Correspondence to:** Abdul Kader Mohiuddin; Assistant Professor Department of Pharmacy, World University of Bangladesh 151/8, Green Road, Dhanmondi, Dhaka - 1205, Bangladesh; Tel: +8801716477485; E-mail: mohiuddin3@pharmacy.wub.edu.bd

Received: June 22nd, 2019; **Revised:** July 25th, 2019; **Accepted:** June 24th, 2019; **Published:** August 3rd, 2019

Citation: Mohiuddin AK. Domination of gastric complications among diabetic patients. *Gastro Open A Open J*. 2019; I(1): 1-5

ABSTRACT

This article covers the study of disease transmission, pathophysiology/complexities and the board of Diabetic Gastroparesis (DGP), and even more extensively diabetic gastro enteropathy, which incorporates all the gastrointestinal appearances of Diabetes Mellitus (DM). Hyperglycemia, autonomic neuropathy, and enteric neuromuscular aggravation and damage are ensnared in the pathogenesis of postponed Gastric Exhausting (GE). Introductory choices incorporate dietary alterations, supplemental oral sustenance, and antiemetic and prokinetic prescriptions. Patients with progressively extreme side effects may require a venting gastrostomy or jejunostomy as well as Gastric Electrical Stimulation (GES). Until this point, a couple of population-based investigations have evaluated the genuine prevalence and occurrence of gastroparesis. In any case, its prevalence seems, by all accounts, to be ascending, as does its rate among minority populations, reported by means of hospitalizations, which can force huge economic burdens on patients.


Keywords: Diabetes; Delayed Gastric Emptying; Dyspepsia; Gastroparesis; Gastric Electrical Stimulation; Pyloric Dysfunction.

Abbreviations

DM: Diabetes Mellitus; DGP: Diabetic Gastroparesis; FD: Functional Dyspepsia; FDA: Food and Drug Administration; GE: Gastric Emptying; GP: Gastroparesis; GERD: Gastroesophageal Reflux Disease; GES: Gastric Electrical Stimulation; HFS: High-Frequency Stimulation; IGP: Idiopathic Gastroparesis; G-POEM: Peroral Endoscopic Pyloromyotomy; RCTs: Randomized Controlled Trials.

INTRODUCTION

Figure 1. Fluoroscopic images of the Gastric Electrical Stimulator (GES) and its leads during Gastric Peroral Endoscopic Pyloromyotomy (G-POEM).¹ Gastric Electrical Stimulators (GESs) have been used to treat refractory gastroparesis in patients who fail initial therapies such as dietary modifications, control of psychological stressors and pharmacologic treatment. More recently, Gastric Peroral Endoscopic Pyloromyotomy (G-POEM) has emerged as a novel endoscopic technique to treat refractory gastroparesis. A series of fluoroscopic images, each from a different G-POEM case, show the implanted gastric electrical stimulator (blue arrow) and its leads (red arrow). The GES leads are located in different parts of the stomach during each case.



Up to 50% of patients with type 1 and 2 Diabetes Mellitus (DM) and suboptimal glycemic control have delayed Gastric Emptying (GE), which can be documented with scintigraphy, 13 C-breath tests, or a

wireless motility capsule; the remainder have normal or rapid GE.^{2,4} Also, it has been determined that 29% of patients with GP had DM,⁵ 13% developed symptoms after gastric surgery and 36% were idiopathic. About 12% of global health care expenditure (\$727 billion) is spent on diabetes. When expanded to the age group between 18 and 99 years, the cost would total to \$850 billion. In conjunction with the rising prevalence, the cost is expected to rise to a staggering \$958 billion by 2045. In the USA, an estimated 5 million patients suffer from some form of Gastroparesis (GP) and the female: male ratio is 4:1. Many patients with delayed GE are asymptomatic; others have dyspepsia (i.e., mild-moderate indigestion, with or without a mild delay in GE) or GP, which is a syndrome, characterized by moderate-severe upper gastrointestinal symptoms and delayed GE that suggests, but are not accompanied by gastric outlet obstruction.⁶ GP can markedly impair quality of life and up to 50% of patients have significant anxiety and/or depression.^{2,7-9} Woodhouse et.al, 2017 reported combined anxiety/ depression in 24%, severe anxiety in 12%, depression in 23%, and somatization is 50%.⁷ In diabetic patients (without neuropathy) and healthy controls, acute hyperglycemia will instead relax the proximal stomach, and suppress gastric electrical activity (e.g., reduced the frequency, propagation, and contraction of the antrum) in both fasting and post-prandial conditions,

thereby slowing gastric emptying.¹⁰ Abdominal pain is often epigastric (43%), postprandial (72%), nocturnal (74%), and frequently associated with interference with sleep (66%).⁸ Early satiety (88%), and bloating (64%) were the most common symptoms, however, 94% of patients had a resolution of their symptoms a year after their operation.¹¹ Severe/very severe upper abdominal pain occurred in 34% of GP patients and associated with other GP symptoms, somatization, and opiate medication use.¹² Nausea and vomiting are more common in DGP whereas abdominal pain and early satiety are more frequent in idiopathic GP. The 3 main causes of GP are diabetic, postsurgical, and idiopathic.¹³ Although GP is frequently associated with diabetes (DGP), Idiopathic Gastroparesis (IGP) accounts for the majority of cases (60%).¹⁴ In diabetes, measuring gastric emptying has an additional justification in determining the absorption of orally administered drugs and nutrients, and thus postprandial glucose regulation. Indeed, new-onset or worsening of existing difficulties in blood glucose regulation may be the first symptom of DGP.³ Growing clinical evidence shows that delayed GE (in GP patients) may be a factor associated with severe reflux, dyspepsia, or both. GP, concomitant in 25% of patients with Gastro-Esophageal Reflux Disease (GERD), has been shown to improve after Nissen fundoplication.¹⁵ Treatment consists of a combination of lifestyle and dietary medication, medications (antiemetics, prokinetics, neuromodulators, and accommodation-enhancers), alternative and complementary therapy, endoscopic therapy (pyloric-directed therapy, temporary stimulation, jejunostomy, or venting gastrostomy) and surgical therapy (pyloroplasty, gastric electrical stimulation, and gastrectomy).¹⁶ In patients with GP, etiologies, symptom severity, and treatments vary among races and ethnicities and between sexes.¹⁷ If a doctor suspects a person with diabetes has GP, he will typically order one or more of the following tests to confirm the diagnosis: Barium X-ray; Barium beefsteak test; Radioisotope gastric-emptying scan; Gastric manometry Blood tests to check for nutritional deficiencies and electrolyte imbalances that are common with GP; Imaging of the gallbladder, kidneys, and pancreas to rule out gallbladder problems, kidney disease, or pancreatitis as causes; An upper endoscopy to check for abnormalities in the structure of the stomach.¹⁸ It is critical to clearly distinguish patients with Functional Dyspepsia (FD) from those with GP and to better understand the relationship among alterations in specific symptoms, GE, and altered peripheral and central sensory responses to gastric stimuli.¹⁹ Placebos have been tested in comparison to treatments for GP; however, results general are mixed. For example, Brewer et.al, 2019 reported that randomized controlled trials (RCTs) on drug treatments have found placebos can marginally improve overall GP-related symptom scores but placebo effects did not improve gastric emptying.²⁰ A similar situation may occur in a misguided attempt to improve gastric health by using the ubiquitously prescribed proton pump inhibitors, H2 receptor antagonists, and sucralfate or aluminum hydroxide-based antacids. These drugs are a cause of delayed gastric emptying. Such “therapeutic adventures”, akin to a pyromaniac leading a firefighting operation, may harm rather than improve DGP. A combination of acid-suppressing and prokinetic drugs is indicated only if dyspepsia and GP co-exist with each other.²¹ Vagal dysfunction has also been postulated to play a role in DGP. When food is ingested and gastric accommodation is impaired, patients may experience symptoms such as early satiation, fullness, and discomfort. Animal and human data suggest that vagal neuropathy can lead to a reduction in pyloric relaxation, impaired antral contraction and disturbed antro-pyloric coordination.²² GP has also been associated with bronchiectasis, aspiration and chronic rejection. GI bleeding secondary to severe re-

fractory esophagitis with an eventual necessity for surgery has also been reported.²³ Most patients respond to conservative treatment with frequent small meals and an upright seating position, in combination with motility agents, such as oral erythromycin analogs, metoclopramide, and domperidone (the last of these is not FDA approved in the US).^{24,25} Metoclopramide and domperidone, a D2 dopamine receptor antagonist, are the most widely used but only metoclopramide is FDA approved in the US while domperidone is available in Europe, Canada, Mexico, and New Zealand.²⁶ Metoclopramide acts on several different receptors; primarily as a dopamine receptor antagonist, both peripherally improving gastric emptying, and centrally resulting in an anti-emetic effect.^{27,28} Metoclopramide side effects, mostly related to its ability to cross the blood-brain barrier, include drowsiness, restlessness, hyperprolactinemia, and Tardive Dyskinesia (TD) (when taken more than 12 wk), a movement disorder that may be irreversible.²⁹⁻³¹ Other groups of medication, such as 5-HT3 receptor antagonists, phenothiazines, and muscarinic cholinergic receptor antagonist, have been used off-label for symptomatic relieve but they do not have the effect of gastric motility. While medications and dietary modification are the first-line treatment, approximately 30% of patients do not respond to conservative management. These limitations of medical therapy highlight the need for an alternative therapeutic option.³²⁻³⁶ Traditional therapy for delayed gastric emptying has focused on supportive treatment, and there is no significant effective therapy. The low-energy shock wave can increase gastric contraction and empty by activating axonal regeneration and increasing myenteric plexus, but not related with motility peptides.^{4,37-39} Gastric Electrical Stimulation (GES) (Enterra, Medtronic, Inc.) was approved by US Food and Drug Administration (FDA) in 2000 as a Humanitarian Use Device for patients with refractory diabetic or idiopathic GP.⁴⁰⁻⁴² On the other hand, High-Frequency Stimulation (HFS) has no effect on gastric emptying but is able to significantly reduce symptoms of nausea and vomiting in gastroparesis patients.^{43,44} Compared to the use of single-point electrodes, the use of two low-resolution electrodes allows recording gastric electrical wave propagation with greater detail. Low-resolution recording appears to be superior to single point recordings while awaiting practical high-resolution recordings.⁴⁵ Abell et.al, 2019 concluded that electrical stimulation improves symptoms and physiology with (a) an early and sustained anti-emetic effect; (b) an early and durable gastric prokinetic effect in delayed emptying patients; (c) an early anti-arrhythmic effect that continues over time; (d) a late autonomic effect; (e) a late hormonal effect; (f) an early anti-inflammatory effect that persists; and (g) an early and sustained improvement in health-related quality of life.⁴⁶ GES improved symptoms in 75% of patients with 43% being at least moderately improved. Nausea, loss of appetite, and early satiety responded the best.^{47,48} Pain management is essential, as nearly 90% of patients report symptoms of epigastric pain.²³ Pyloric dysfunction has been described in a subset of patients with GP, prompting experimentation with botulinum toxin injections into the pylorus, which is relatively safe and has been successfully used in other gastrointestinal disorders.⁴⁹ The measurement of GE using a precise technique such as scintigraphy, which remains as the gold standard, nonetheless provides important mechanistic information when considering the effects on nutrient absorption, postprandial glycemic responses in diabetes, or potential tachyphylaxis.⁵⁰ Advances to better understand the pathophysiology and management of DGP have been limited, especially with discordance between symptoms and severity of delay in gastric emptying. Established treatment options are limited; however, recent pharmacologic and surgical interventions show promise.⁵¹

CONCLUSION

TDGP is a dysfunction in the autonomic and enteric nervous systems exasperated by chronic hyperglycemia. Not sole but rather a significant cure lies with exacting glucose monitoring and control. Some diabetic patients may moreover experience changes in gastric compliance; both expanded or diminished, which may likewise add to delayed gastric emptying. The board of DGP includes a way of life alterations, glyce-mic control, pharmacological drugs, and for recalcitrant cases surgical medicines. Dietary changes incorporate changing to little regular small meals, low-fat eating routine. Drinks, for example, carbonated and alcoholic refreshments and sustenance wealthy in insoluble fiber ought to be kept away from totally. Likewise, stopping smoking has additionally been accounted for to be useful. Surgical methodologies incorporate venting gastrectomy, feeding jejunostomy; pyloroplasty and partial gastrectomy are performed when medical therapy fails. Another rising, less intrusive endoscopic method Gastric Peroral Endoscopic Myotomy (G-POEM) is being assessed to the diminish the manifestations of GP. The underlying investigations are empowering, will need further examinations to assess efficacy and safety.

ACKNOWLEDGMENT

It is a great honor and gratitude to be pharmacists in research and education process. I am thankful to Dr. Mamun Rashid, Assistant Professor of Pharmaceutics, and Appalachian College of Pharmacy Oakwood, Virginia for his precious time to review my article and for his thoughtful suggestions. I am also grateful to seminar library of the Faculty of Pharmacy, University of Dhaka and BANSDOC Library, Bangladesh for providing me books, journal, and newsletters.

FINANCIAL DISCLOSURE OR FUNDING

No.

REFERENCES

- Koul A, Dacha S, Mekaroonkamol P, Li X, Li L, et al. Fluoroscopic gastric peroral endoscopic pyloromyotomy (G-POEM) in patients with a failed gastric electrical stimulator. *Gastroenterol Rep (Oxf)*. 2018; 6(2): 122-126. doi: [10.1093/gastro/gox040](https://doi.org/10.1093/gastro/gox040)
- Bharucha AE, Kudva YC, Prichard DO. Diabetic Gastroparesis. *Endocr Rev*. 2019. doi: [10.1210/er.2018-00161](https://doi.org/10.1210/er.2018-00161)
- Sangnes DA, Søfteland E, Teigland T, Dimcevski G. Comparing radiopaque markers and (13)C-labelled breath test in diabetic gastroparesis diagnostics. *Clin Exp Gastroenterol*. 2019; 12: 193-201. doi: [10.2147/CEG.S200875](https://doi.org/10.2147/CEG.S200875)
- Wu KL, Chiu YC, Yao CC, Tsai CE, Hu ML, et al. Effect of extracorporeal low-energy shock wave on diabetic gastroparesis in a rat model. *J Gastroenterol Hepatol*. 2019; 34(4): 720-727. doi: [10.1111/jgh.14368](https://doi.org/10.1111/jgh.14368)
- Alipour Z, Khatib F, Tabib SM, Javadi H, Jafari E, et al. Assessment of the Prevalence of Diabetic Gastroparesis and Validation of Gastric Emptying Scintigraphy for Diagnosis. *Mol Imaging Radionucl Ther*. 2017; 26(1): 17-23. doi: [10.4274/mirt.61587](https://doi.org/10.4274/mirt.61587)
- Krishnasamy S, Abell TL Diabetic gastroparesis: Principles and current trends in management. *Diabetes Ther*. 2018; 9(Suppl 1): 1-42. doi: [10.1007/s13300-018-0454-9](https://doi.org/10.1007/s13300-018-0454-9)
- Woodhouse S, Hebbard G, Knowles SR. Psychological controversies in gastroparesis: A systematic review. *World J Gastroenterol*. 2018; 23(7): 1298-1309. doi: [10.3748/wjg.v23.i7.1298](https://doi.org/10.3748/wjg.v23.i7.1298)
- Avalos DJ, Sarosiek I, Loganathan P, McCallum RW. Diabetic gastroparesis: current challenges and future prospects. *Clin Exp Gastroenterol*. 2018; 11: 347-363. doi: [10.2147/CEG.S131650](https://doi.org/10.2147/CEG.S131650)
- Teigland T, Iversen MM, Sangnes DA, Dimcevski G, Søfteland E. A longitudinal study on patients with diabetes and symptoms of gastroparesis - associations with impaired quality of life and increased depressive and anxiety symptoms. *J Diabetes Complications*. 2018; 32(1): 89-94. doi: [10.1016/j.jdiacomp.2017.10.010](https://doi.org/10.1016/j.jdiacomp.2017.10.010)
- Aswath GS, Foris LA, Patel K. Diabetic Gastroparesis. 2018; Treasure Island (FL): Stat Pearls.
- Liu N, Abell T. Gastroparesis updates on pathogenesis and management. *Gut Liver*. 2017; 11(5): 579-589. doi: [10.5009/gnl16336](https://doi.org/10.5009/gnl16336)
- Parkman HP, Wilson LA, Hasler WL, McCallum RW, Sarosiek I, et al. Abdominal pain in patients with gastroparesis: Associations with gastroparesis symptoms, etiology of gastroparesis, gastric emptying, somatization, and quality of life. *Dig Dis Sci*. 2019; 64(8): 2242-2255. doi: [10.1007/s10620-019-05522-9](https://doi.org/10.1007/s10620-019-05522-9)
- Shen S, Xu J, Lamm V, Vachaparambil CT, Chen H. Diabetic gastroparesis and nondiabetic gastroparesis. *Gastrointest Endosc Clin N Am*. 2019; 29(1): 15-25. doi: [10.1016/j.giec.2018.08.002](https://doi.org/10.1016/j.giec.2018.08.002)
- Strijbos D, Keszhelyi D, Smeets FGM, Kruijmel J, Gilissen LPL, et al. Therapeutic strategies in gastroparesis: Results of stepwise approach with diet and prokinetics, Gastric Rest, and PEG-J: A retrospective analysis. *Neurogastroenterol Motil*. 2019; 31(6): e13588. doi: [10.1111/nmo.13588](https://doi.org/10.1111/nmo.13588)
- Noar MD, Noar E. Gastroparesis associated with gastroesophageal reflux disease and corresponding reflux symptoms may be corrected by radiofrequency ablation of the cardia and esophagogastric junction. *Surg Endosc*. 2008; 22(11): 2440-2444. doi: [10.1007/s00464-008-9873-4](https://doi.org/10.1007/s00464-008-9873-4)
- Onyimba FU, Clarke JO. Helping Patients with Gastroparesis. *Med Clin North Am*. 2019; 103(1): 71-87. doi: [10.1016/j.mcna.2018.08.013](https://doi.org/10.1016/j.mcna.2018.08.013)
- Parkman HP, Yamada G, Van Natta ML, Yates K, Hasler WL Ethnic, racial, and sex differences in etiology, symptoms, treatment, and symptom outcomes of patients with gastroparesis. *Clin Gastroenterol Hepatol*. 2019; 17(8): 1489-1499.e8. doi: [10.1016/j.cgh.2018.10.050](https://doi.org/10.1016/j.cgh.2018.10.050)
- Fletcher J What to know about diabetic gastroparesis? 2019.
- Kim BJ, Kuo B. Gastroparesis and Functional Dyspepsia: A Blurring Distinction of Pathophysiology and Treatment. *J Neurogastroenterol*

- Motil.* 2019; 25(1): 27-35. doi: [10.5056/jnm18162](https://doi.org/10.5056/jnm18162)
20. Brewer Gutierrez OI, Khashab MA. Stent placement for the treatment of gastroparesis. *Gastrointest Endosc Clin N Am.* 2019; 29(1): 107-115. doi: [10.1016/j.giec.2018.08.011](https://doi.org/10.1016/j.giec.2018.08.011)
21. Kalra S, Sharma A, Priya G. Diabetic gastroparesis. *Diabetes Ther.* 2018; 9(5): 1723-1728. doi: [10.1007/s13300-018-0475-4](https://doi.org/10.1007/s13300-018-0475-4)
22. Christophe Vanormelingen, Jan Tack, Christopher N Andrews, Diabetic gastroparesis. *British Medical Bulletin.* 2013; 105(1): 213-230. doi: [10.1093/bmb/ldt003](https://doi.org/10.1093/bmb/ldt003)
23. Navas CM, Patel NK, Lacy BE. Symptomatic management of gastroparesis. *Gastrointest Endosc Clin N Am.* 2019; 29(1): 55-70. doi: [10.1016/j.giec.2018.08.005](https://doi.org/10.1016/j.giec.2018.08.005)
24. Naik-Mathuria B, Jamous F, Noon GP, Loebe M, Seethamraju H, et al. Severe gastroparesis causing splenic rupture: A unique, early complication after heart-lung transplantation. *Tex Heart Inst J.* 2006; 33(4): 508-511.
25. Akindipe OA, Faul JL, Vierra MA, Triadafilopoulos G, Theodore J The surgical management of severe gastroparesis in heart/lung transplant recipients. *Chest.* 2000; 117(3): 907-910. doi: [10.1378/chest.117.3.907](https://doi.org/10.1378/chest.117.3.907)
26. Waseem S, Moshiree B, Draganov PV. Gastroparesis: Current diagnostic challenges and management considerations. *World J Gastroenterol.* 2009; 15(1): 25-37. doi: [10.3748/wjg.15.25](https://doi.org/10.3748/wjg.15.25)
27. Sanger GJ, Andrews PLR A. History of Drug discovery for treatment of nausea and vomiting and the implications for future research. *Front Pharmacol.* 2018; 9: 913. doi: [10.3389/fphar.2018.00913](https://doi.org/10.3389/fphar.2018.00913)
28. Abd Ellah NH, Ahmed EA, Abd-Ellatief RB, Ali MF, Zahran AM, et al. Metoclopramide nanoparticles modulate immune response in a diabetic rat model: Association with regulatory T cells and proinflammatory cytokines. *Int J Nanomedicine.* 2019; 14: 2383-2395. doi: [10.2147/IJN.S196842](https://doi.org/10.2147/IJN.S196842)
29. Lee A, Kuo B. Metoclopramide in the treatment of diabetic gastroparesis. *Expert Rev Endocrinol Metab.* 2010; (5): 653-662.
30. Shakhathreh M, Jehangir A, Malik Z, Parkman HP. Metoclopramide for the treatment of diabetic gastroparesis. *Expert Rev Gastroenterol Hepatol.* 2019; 13(8): 711-721. doi: [10.1080/17474124.2019.1645594](https://doi.org/10.1080/17474124.2019.1645594)
31. Al-Saffar A, Lennernäs H, Hellström PM. Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited. *Neurogastroenterol Motil.* 2019; 2: e13617. doi: [10.1111/nmo.13617](https://doi.org/10.1111/nmo.13617)
32. Mekaroonkamol P, Shah R, Cai Q. Outcomes of per oral endoscopic pyloromyotomy in gastroparesis worldwide. *World J Gastroenterol.* 2019; 25(8): 909-922. doi: [10.3748/wjg.v25.i8.909](https://doi.org/10.3748/wjg.v25.i8.909)
33. Williams PA, Nikitina Y, Kedar A, Lahr CJ, Helling TS, et al. Long-term effects of gastric stimulation on gastric electrical physiology. *J Gastrointest Surg.* 2013; 17(1): 50-55; discussion p.55-6. doi: [10.1007/s11605-012-2020-5](https://doi.org/10.1007/s11605-012-2020-5)
34. Hasler WL. Newest Drugs for Chronic Unexplained Nausea and Vomiting. *Curr Treat Options Gastroenterol.* 2016; 14(4): 371-385. doi: [10.1007/s11938-016-0110-2](https://doi.org/10.1007/s11938-016-0110-2)
35. Hasler WL. Gastroparesis-current concepts and considerations. *Medscape J Med.* 2008; 10(1): 16.
36. Camilleri M. Pharmacological agents currently in clinical trials for disorders in neurogastroenterology. *J Clin Invest.* 2013; 123(10): 4111-4120. doi: [10.1172/JCI70837](https://doi.org/10.1172/JCI70837)
37. Atassi H, Abell TL. Gastric electrical stimulator for treatment of gastroparesis. *Gastrointest Endosc Clin N Am.* 2019; 29(1): 71-83. doi: [10.1016/j.giec.2018.08.013](https://doi.org/10.1016/j.giec.2018.08.013)
38. Meldgaard T, Olesen SS, Farmer AD, Krogh K, Wendel AA, et al. Diabetic enteropathy: From molecule to mechanism-based treatment. *J Diabetes Res.* 2018; 3827301. doi: [10.1155/2018/3827301](https://doi.org/10.1155/2018/3827301)
39. Demedts I, Masaoka T, Kindt S, De Hertogh G, Geboes K, et al. Gastrointestinal motility changes and myenteric plexus alterations in spontaneously diabetic bio breeding rats. *J Neurogastroenterol Motil.* 2013; 19(2): 161-170. doi: [10.5056/jnm.2013.19.2.161](https://doi.org/10.5056/jnm.2013.19.2.161)
40. Hasanin M, Amin O, Hassan H, Kedar A, Griswold M, et al. Temporary gastric stimulation in patients with gastroparesis symptoms: low-resolution mapping multiple versus single mucosal lead electrograms. *Gastroenterology Res.* 2019; 12(2): 60-66. doi: [10.14740/gr1127](https://doi.org/10.14740/gr1127)
41. McCallum RW, Sarosiek I, Parkman HP, Snape W, Brody F, et al. Gastric electrical stimulation with Enterra therapy improves symptoms of idiopathic gastroparesis. *Neurogastroenterol Motil.* 2013; 25(10): 815-e636. doi: [10.1111/nmo.12185](https://doi.org/10.1111/nmo.12185)
42. Lin Z, Forster J, Sarosiek I, McCallum RW. Treatment of gastroparesis with electrical stimulation. *Dig Dis Sci.* 2003; 48(5): 837-848. doi: [10.1023/a:1023099206939](https://doi.org/10.1023/a:1023099206939)
43. Chu H, Lin Z, Zhong L, McCallum RW, Hou X. Treatment of high-frequency gastric electrical stimulation for gastroparesis. *J Gastroenterol Hepatol.* 2012; 27(6): 1017-1026. doi: [10.1111/j.1440-1746.2011.06999.x](https://doi.org/10.1111/j.1440-1746.2011.06999.x)
44. Pasricha TS, Pasricha PJ. Botulinum Toxin Injection for Treatment of Gastroparesis. *Gastrointest Endosc Clin N Am.* 2019; 29(1): 97-106. doi: [10.1016/j.giec.2018.08.007](https://doi.org/10.1016/j.giec.2018.08.007)
45. Rayner CK, Jones KL, Horowitz M. Is Making the stomach pump better the answer to gastroparesis? *Gastroenterology.* 2019; 156(6): 1555-1557. doi: [10.1053/j.gastro.2019.03.030](https://doi.org/10.1053/j.gastro.2019.03.030)
46. Abell TL, Kedar A, Stocker A, Beatty K, McElmurray L. Gastroparesis syndromes: Response to electrical stimulation. *Neurogastroenterol*

Motil. 2019; 31(3): e13534. doi: [10.1111/nmo.13534](https://doi.org/10.1111/nmo.13534)

47. Heckert J, Sankineni A, Hughes WB, Harbison S, Parkman H. Gastric electric stimulation for refractory gastroparesis: A prospective analysis of 151 patients at a single center. *Dig Dis Sci.* 2016; 61(1): 168-75. doi: [10.1007/s10620-015-3837-z](https://doi.org/10.1007/s10620-015-3837-z)

48. Parkman HP Upper GI. Disorders: Pathophysiology and current therapeutic approaches. *Handb Exp Pharmacol.* 2017; 239: 17-37. doi: [10.1007/164_2016_114](https://doi.org/10.1007/164_2016_114)

49. Parkman HP, Chapter 1. Upper GI Disorders: Pathophysiology and Current Therapeutic Approaches. In: *Gastrointestinal Pharmacology* 2017; 17-37.

50. Parkman HP Chapter 24. Gastroparesis, Postprandial Distress. In: *Gastrointestinal Motility Disorders.* 2017; 269-281.

51. Kumar M, Chapman A, Javed S, Alam U, Malik RA, et al. The investigation and treatment of diabetic gastroparesis. *Clin Ther.* 2018; 40(6): 850-861. doi: [10.1016/j.clinthera.2018.04.012](https://doi.org/10.1016/j.clinthera.2018.04.012)